NCT04544410终止2 期
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects With Classic Congenital Adrenal Hyperplasia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Change in Total Daily GC Dose in Subjects With Classic CAH Over the 24-week, Double Blind, Placebo-Controlled Treatment Period
研究概览
简要总结
An investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid dosing in classic Congenital adrenal hyperplasia (CAH) subjects up to 76 weeks of treatment. Optional open label extension up to 240 weeks.
详细描述
This is a study that evaluated the ability of tildacerfont to reduce the glucocorticoid steroid dose used by adult subjects with CAH. The first 24-weeks were a double-blind, placebo controlled, comparison of tildacerfont vs placebo. The following 52-weeks allowed all subjects to move to open label tildacerfont to continue to reduce steroid dose where appropriate, and observe long term safety. Subjects were offered a long term open label extension up to 240 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
Double-Blind for first 24 weeks, then open label
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects ≥18 years old at screening
- •Has a known childhood diagnosis of classic CAH due to 21-hydroxylase deficiency based on genetic mutation in CYP21A2 and/or documented (at any time) elevated 17-hydroxyprogesterone (17-OHP) and currently treated with hydrocortisone (HC), HC acetate, prednisone, prednisolone, methylprednisolone, dexamethasone (or a combination of the aforementioned glucocorticoid [GCs])
- •Has lower limit of detection ≤ androstenedione (A4) ≤ 2.5x upper limit of normal (ULN) at screening measured before a morning GC dose
- •Has been on a stable, supraphysiologic dose of GC replacement (defined as ≥30 mg/day and ≤60 mg/day in HCe) for ≥1 month before screening
- •For subjects with the salt-wasting form of CAH, subject has been on a stable dose of mineralocorticoid replacement for ≥1 month before screening
- •Agrees to follow contraception guidelines. Male subjects must also agree to refrain from donating sperm throughout the Treatment Period and for 90 days after the last dose of study drug
- •Is able to understand all study procedures and risks involved and provides written informed consent indicating willingness to comply with all aspects of the protocol
排除标准
- •Has a known or suspected diagnosis of any other known form of classic CAH (not due to 21-hydroxylase deficiency)
- •Has a history that includes bilateral adrenalectomy or hypopituitarism
- •Has a history of allergy or hypersensitivity to tildacerfont, any of its excipients, or any other CRF1 receptor antagonist
- •Shows clinical signs or symptoms of adrenal insufficiency
- •Has had a clinically significant unstable medical condition, medically significant illness, or chronic disease occurring within 30 days of screening, including but not limited to:
- •An ongoing malignancy or <3 years of remission history from any malignancy, other than successfully treated localized skin cancer
- •eGFR of <45 mL/min/1.73 m2
- •Current or history of liver disease (with the exception of Gilbert's syndrome)
- •History of alcohol or substance abuse within the last year, or any significant history of alcohol or substance abuse that would likely prevent the subject from reliably participating in the study, based on the opinion of the Investigator
- •Active hepatitis B, hepatitis C, or HIV at screening
- •Subjects who plan to undergo bariatric surgery during the study are excluded
- •Any other condition that would impact subject safety or confound interpretation of study results
- •Psychiatric conditions, including but not limited to bipolar disorder, schizophrenia, or schizoaffective disorders that are not effectively controlled on medication and may have an adverse impact on study compliance. Symptoms including hallucinations, delusions, and psychosis are exclusionary. Additionally:
- •Increased risk of suicide based on the Investigator's judgment or the results of the C-SSRS conducted at screening and baseline (eg, C-SSRS Type 3, 4, or 5 ideation within the past 6 months or any suicidal behavior within the past 12 months) b. Hospital Anxiety and Depression Scale (HADS) score >12 for either depression or anxiety at screening or baseline
- •Has clinically significant abnormal ECG or clinical laboratory results. Abnormal results that must be reviewed and discussed with the Medical Monitor to determine eligibility for this study include but are not limited to:
- •Any clinically meaningful abnormal ECG results, including QTcF >450 ms for male participants or >470 ms for female participants
- •ALT >2x ULN
- •Total bilirubin >1.5x ULN
- •Total bile acids >5x ULN
- •Routinely works overnight shifts
- •Subjects with travel plans/work schedules that result in significant and frequent changes in time zones (>2 hours) will require Medical Monitor approval for enrollment
- •Females who are pregnant or nursing
- •Use of any other investigational drug from 30 days or 5 half-lives (whichever is longer) before screening to the end of the study
- •Use of the following drugs from 30 days or 5 half-lives (whichever is longer) before the start of the Treatment Period to the end of the study:
- •Rosiglitazone, aromatase inhibitors, testosterone, growth hormones, or any other medication or supplement that could impact subject safety or confound interpretation of study results
- •The drugs which are:
- •i. Moderate to strong inhibitors and/or inducers of CYP3A4 ii. Sensitive substrates or narrow-therapeutic-range substrates of CYP3A4 (except hormonal contraception containing ≤35 μg ethinyl estradiol) iii. Sensitive substrates or narrow-therapeutic-range substrates of BCRP (except those that can be administered QD in the morning, separated by approximately 10 hours from evening administration of study drug)
- •Donation or receipt of blood from 90 days before Screening to the end of the study; donation or receipt of platelets, white blood cells, or plasma from 30 days before Screening to the end of the study
研究组 & 干预措施
Tildacerfont Group
Experimental
Tildacerfont administered daily via oral tablet for 24 weeks at dose level 1; followed by open label tildacerfont for 52 weeks
干预措施: Tildacerfont/Placebo (Drug)
Placebo
Placebo Comparator
Placebo administered daily via oral tablet for 24 weeks; followed by open label tildacerfont for 52 weeks
干预措施: Tildacerfont/Placebo (Drug)
结局指标
主要结局
Change in Total Daily GC Dose in Subjects With Classic CAH Over the 24-week, Double Blind, Placebo-Controlled Treatment Period
时间窗: 24 Weeks
Absolute change from baseline (Day 1) in GC dose in HCe at Week 24. The analysis of absolute change in total daily GC dose in HCe will include data from Weeks 3, 6, 12, 18 and 24 in a mixed model
次要结局
- Effect of Tildacrfont in Reducing GC Use to Near-physiologic Levels While Maintaining Androgen Control in Subjects With CAH(24 Weeks)
- Effectiveness in Reducing Cardiovascular Risk in Subjects With CAH(24 Weeks)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
4 期
Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus NephritisLupus NephritisNCT05207358Institutul Clinic Fundeni30
已完成
4 期
Mineralocorticoid Receptor Antagonists in Type 2 DiabetesDiabetes Type 2NCT02809963Herlev Hospital140
已完成
4 期
Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseHyperglycemia Steroid-inducedNCT02253121Slotervaart Hospital46
已完成
1 期
Glucocorticoid Receptor Antagonism in Subclinical CushingsSubclinical Cushing'sNCT00721201Sheffield Teaching Hospitals NHS Foundation Trust6
招募中
4 期
Taper Or Abrupt Steroid Stop: TOASSTtrialInflammatory DisorderAutoimmuneNCT03153527University Hospital, Basel, Switzerland530